292 related articles for article (PubMed ID: 37842166)
1. CRISPR-Cas9 delivery strategies with engineered extracellular vesicles.
Lu Y; Godbout K; Lamothe G; Tremblay JP
Mol Ther Nucleic Acids; 2023 Dec; 34():102040. PubMed ID: 37842166
[TBL] [Abstract][Full Text] [Related]
2. Engineered Cas9 extracellular vesicles as a novel gene editing tool.
Osteikoetxea X; Silva A; Lázaro-Ibáñez E; Salmond N; Shatnyeva O; Stein J; Schick J; Wren S; Lindgren J; Firth M; Madsen A; Mayr LM; Overman R; Davies R; Dekker N
J Extracell Vesicles; 2022 May; 11(5):e12225. PubMed ID: 35585651
[TBL] [Abstract][Full Text] [Related]
3. Encapsulating Cas9 into extracellular vesicles by protein myristoylation.
Whitley JA; Kim S; Lou L; Ye C; Alsaidan OA; Sulejmani E; Cai J; Desrochers EG; Beharry Z; Rickman CB; Klingeborn M; Liu Y; Xie ZR; Cai H
J Extracell Vesicles; 2022 Apr; 11(4):e12196. PubMed ID: 35384352
[TBL] [Abstract][Full Text] [Related]
4. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading.
Liang Y; Iqbal Z; Wang J; Xu L; Xu X; Ouyang K; Zhang H; Lu J; Duan L; Xia J
Biomater Sci; 2022 Jul; 10(15):4095-4106. PubMed ID: 35766814
[TBL] [Abstract][Full Text] [Related]
5. Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing.
Duan L; Ouyang K; Wang J; Xu L; Xu X; Wen C; Xie Y; Liang Y; Xia J
Chembiochem; 2021 Dec; 22(24):3360-3368. PubMed ID: 34418266
[TBL] [Abstract][Full Text] [Related]
6. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing.
Whitley JA; Cai H
J Extracell Vesicles; 2023 Sep; 12(9):e12343. PubMed ID: 37723839
[TBL] [Abstract][Full Text] [Related]
7. The CRISPR/Cas9 System Delivered by Extracellular Vesicles.
Zhu X; Gao M; Yang Y; Li W; Bao J; Li Y
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986843
[TBL] [Abstract][Full Text] [Related]
8. New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment.
Yan B; Liang Y
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555398
[TBL] [Abstract][Full Text] [Related]
9. Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing.
Yao X; Lyu P; Yoo K; Yadav MK; Singh R; Atala A; Lu B
J Extracell Vesicles; 2021 Mar; 10(5):e12076. PubMed ID: 33747370
[TBL] [Abstract][Full Text] [Related]
10. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
11. Preparation of NanoMEDIC Extracellular Vesicles to Deliver CRISPR-Cas9 Ribonucleoproteins for Genomic Exon Skipping.
Watanabe K; Gee P; Hotta A
Methods Mol Biol; 2023; 2587():427-453. PubMed ID: 36401042
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
[TBL] [Abstract][Full Text] [Related]
13. Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies.
Xu Q; Zhang Z; Zhao L; Qin Y; Cai H; Geng Z; Zhu X; Zhang W; Zhang Y; Tan J; Wang J; Zhou J
J Control Release; 2020 Oct; 326():455-467. PubMed ID: 32711027
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 Genome Editing vs. Over-Expression for Fluorescent Extracellular Vesicle-Labeling: A Quantitative Analysis.
Strohmeier K; Hofmann M; Hauser F; Sivun D; Puthukodan S; Karner A; Sandner G; Le Renard PE; Jacak J; Mairhofer M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008709
[TBL] [Abstract][Full Text] [Related]
15. TOP-EVs: Technology of Protein delivery through Extracellular Vesicles is a versatile platform for intracellular protein delivery.
Ilahibaks NF; Ardisasmita AI; Xie S; Gunnarsson A; Brealey J; Vader P; de Jong OG; de Jager S; Dekker N; Peacock B; Schiffelers RM; Sluijter JPG; Lei Z
J Control Release; 2023 Mar; 355():579-592. PubMed ID: 36746337
[TBL] [Abstract][Full Text] [Related]
16. Autophagy inhibitors enhance biomolecular delivery efficiency of extracellular vesicles.
Zhang Y; Huang M; Jiang L; Li T; Wang J; Zhao L; Zhou J
Biochem Biophys Res Commun; 2022 May; 603():130-137. PubMed ID: 35287054
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in CRISPR/Cas9 Delivery Strategies.
Yip BH
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
19. Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene.
Majeau N; Fortin-Archambault A; Gérard C; Rousseau J; Yaméogo P; Tremblay JP
Mol Ther; 2022 Jul; 30(7):2429-2442. PubMed ID: 35619556
[TBL] [Abstract][Full Text] [Related]
20.
Ye Y; Shi Q; Yang T; Xie F; Zhang X; Xu B; Fang J; Chen J; Zhang Y; Li J
Technol Cancer Res Treat; 2022; 21():15330338221085370. PubMed ID: 35315725
[No Abstract] [Full Text] [Related]
[Next] [New Search]
